EP3765024
Ný lyfjasamsetning sem inniheldur tvíþætt NK-1/NK-3 viðtaka-mótlyf.
:
EP einkaleyfi í gildi á Íslandi:
13.3.2019:
22.11.2023:
19711866.4
:
12.2.2024:
15.3.2024
:
12.3.2039:
12.3.2026:
31.3.2026
:
NOVEL PHARMACEUTICAL FORMULATION COMPRISING DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS.
13.3.2019
22.11.2023
12.2.2024
15.3.2024
12.3.2026
:
KaNDy Therapeutics Limited:
400 South Oak Way, Reading, Berkshire RG2 6AD, GB
:
TROWER, Mike:
Stevenage Hertfordshire SG1 2FX, GB
:
KERR, Mary:
Stevenage Hertfordshire SG1 2FX, GB
:
ELDER, David:
Hertford, Hertfordshire SG14 2DE, GB
:
LAZARO, Monica:
St. Petersburg, Florida 33716, US
:
BUSH, Derek:
St. Petersburg, Florida 33716, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201862642622 P:
14.3.2018:
US
:
EP2019056303:
13.3.2019
:
C07D 498/04, A61P 5/24, A61K 31/5383, A61K 9/08, A61K 9/48, A61K 47/14, A61P 25/00
: 6
: 23.2.2024
: 12.3.2025
: Árnason Faktor ehf.
: 7
: 26.2.2025
: 12.3.2026
: Árnason Faktor ehf.